These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28867843)

  • 1. Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020.
    Ozawa S; Clark S; Portnoy A; Grewal S; Stack ML; Sinha A; Mirelman A; Franklin H; Friberg IK; Tam Y; Walker N; Clark A; Ferrari M; Suraratdecha C; Sweet S; Goldie SJ; Garske T; Li M; Hansen PM; Johnson HL; Walker D
    Bull World Health Organ; 2017 Sep; 95(9):629-638. PubMed ID: 28867843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
    Li X; Mukandavire C; Cucunubá ZM; Echeverria Londono S; Abbas K; Clapham HE; Jit M; Johnson HL; Papadopoulos T; Vynnycky E; Brisson M; Carter ED; Clark A; de Villiers MJ; Eilertson K; Ferrari MJ; Gamkrelidze I; Gaythorpe KAM; Grassly NC; Hallett TB; Hinsley W; Jackson ML; Jean K; Karachaliou A; Klepac P; Lessler J; Li X; Moore SM; Nayagam S; Nguyen DM; Razavi H; Razavi-Shearer D; Resch S; Sanderson C; Sweet S; Sy S; Tam Y; Tanvir H; Tran QM; Trotter CL; Truelove S; van Zandvoort K; Verguet S; Walker N; Winter A; Woodruff K; Ferguson NM; Garske T;
    Lancet; 2021 Jan; 397(10272):398-408. PubMed ID: 33516338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance.
    Lee LA; Franzel L; Atwell J; Datta SD; Friberg IK; Goldie SJ; Reef SE; Schwalbe N; Simons E; Strebel PM; Sweet S; Suraratdecha C; Tam Y; Vynnycky E; Walker N; Walker DG; Hansen PM
    Vaccine; 2013 Apr; 31 Suppl 2():B61-72. PubMed ID: 23598494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
    Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
    Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
    Constenla D; Liu T
    Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030.
    Carter A; Msemburi W; Sim SY; Gaythorpe KAM; Lambach P; Lindstrand A; Hutubessy R
    Vaccine; 2024 Apr; 42 Suppl 1():S28-S37. PubMed ID: 37537094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.
    Wolfson LJ; Gasse F; Lee-Martin SP; Lydon P; Magan A; Tibouti A; Johns B; Hutubessy R; Salama P; Okwo-Bele JM
    Bull World Health Organ; 2008 Jan; 86(1):27-39. PubMed ID: 18235887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity.
    Stack ML; Ozawa S; Bishai DM; Mirelman A; Tam Y; Niessen L; Walker DG; Levine OS
    Health Aff (Millwood); 2011 Jun; 30(6):1021-8. PubMed ID: 21653952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
    Nonvignon J; Atherly D; Pecenka C; Aikins M; Gazley L; Groman D; Narh CT; Armah G
    Vaccine; 2018 Nov; 36(47):7215-7221. PubMed ID: 29223486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
    Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
    Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules.
    Miller MA; McCann L
    Health Econ; 2000 Jan; 9(1):19-35. PubMed ID: 10694757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the routine childhood immunization program in the United States, 2009.
    Zhou F; Shefer A; Wenger J; Messonnier M; Wang LY; Lopez A; Moore M; Murphy TV; Cortese M; Rodewald L
    Pediatrics; 2014 Apr; 133(4):577-85. PubMed ID: 24590750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.
    Cortés I; Pérez-Camarero S; Del Llano J; Peña LM; Hidalgo-Vega A
    Vaccine; 2013 Aug; 31(35):3473-84. PubMed ID: 23764534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.